Literature DB >> 31341044

The Interferon-Inducible Proteoglycan Testican-2/SPOCK2 Functions as a Protective Barrier against Virus Infection of Lung Epithelial Cells.

Narae Ahn1, Woo-Jong Kim1, Nari Kim1,2, Han Wook Park3, Seung-Woo Lee1,2,3, Joo-Yeon Yoo4,2.   

Abstract

Proteoglycans function not only as structural components of the extracellular compartment but also as regulators of various cellular events, including cell migration, inflammation, and infection. Many microbial pathogens utilize proteoglycans to facilitate adhesion and invasion into host cells. Here we report a secreted form of a novel heparan sulfate proteoglycan that functions against virus infection. The expression of SPOCK2/testican-2 was significantly induced in virus-infected lungs or in interferon (IFN)-treated alveolar lung epithelial cells. Overexpression from a SPOCK2 expression plasmid alone or the treatment of cells with recombinant SPOCK2 protein efficiently blocked influenza virus infection at the step of viral attachment to the host cell and entry. Moreover, mice treated with purified SPOCK2 were protected against virus infection. Sialylated glycans and heparan sulfate chains covalently attached to the SPOCK2 core protein were critical for its antiviral activity. Neuraminidase (NA) of influenza virus cleaves the sialylated moiety of SPOCK2, thereby blocking its binding to the virus. Our data suggest that IFN-induced SPOCK2 functions as a decoy receptor to bind and block influenza virus infection, thereby restricting entry of the infecting virus into neighboring cells.IMPORTANCE Here we report a novel proteoglycan protein, testican-2/SPOCK2, that prevents influenza virus infection. Testican-2/SPOCK2 is a complex type of secreted proteoglycan with heparan sulfate GAG chains attached to the core protein. SPOCK2 expression is induced upon virus infection or by interferons, and the protein is secreted to an extracellular compartment, where it acts directly to block virus-cell attachment and entry. Treatment with purified testican-2/SPOCK2 protein can efficiently block influenza virus infection in vitro and in vivo We also identified the heparan sulfate moiety as a key regulatory module for this inhibitory effect. Based on its mode of action (cell attachment/entry blocker) and site of action (extracellular compartment), we propose testican-2/SPOCK2 as a potential antiviral agent that can efficiently control influenza virus infection.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  SPOCK2; antiviral; extracellular matrix; influenza; proteoglycan

Mesh:

Substances:

Year:  2019        PMID: 31341044      PMCID: PMC6798107          DOI: 10.1128/JVI.00662-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

Review 1.  Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection.

Authors:  Sean Gill; Thomas N Wight; Charles W Frevert
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

Review 2.  Structure and biology of proteoglycans.

Authors:  E Ruoslahti
Journal:  Annu Rev Cell Biol       Date:  1988

Review 3.  Cell surface heparan sulfate and its roles in assisting viral infections.

Authors:  Jian Liu; Suzanne C Thorp
Journal:  Med Res Rev       Date:  2002-01       Impact factor: 12.944

4.  Molecular cloning of testican-2: defining a novel calcium-binding proteoglycan family expressed in brain.

Authors:  C Vannahme; S Schübel; M Herud; S Gösling; H Hülsmann; M Paulsson; U Hartmann; P Maurer
Journal:  J Neurochem       Date:  1999-07       Impact factor: 5.372

5.  Reduced SPOCK1 expression inhibits non-small cell lung cancer cell proliferation and migration through Wnt/β-catenin signaling.

Authors:  T Wang; X Liu; Q Tian; T Liang; P Chang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-02       Impact factor: 3.507

6.  The cellular protein P58IPK regulates influenza virus mRNA translation and replication through a PKR-mediated mechanism.

Authors:  Alan G Goodman; Jennifer A Smith; Siddharth Balachandran; Olivia Perwitasari; Sean C Proll; Matthew J Thomas; Marcus J Korth; Glen N Barber; Leslie A Schiff; Michael G Katze
Journal:  J Virol       Date:  2006-12-13       Impact factor: 5.103

7.  Syndecan-1 Attenuates Lung Injury during Influenza Infection by Potentiating c-Met Signaling to Suppress Epithelial Apoptosis.

Authors:  Rena Brauer; Lingyin Ge; Saundra Y Schlesinger; Timothy P Birkland; Ying Huang; Tanyalak Parimon; Vivian Lee; Bonnie L McKinney; John K McGuire; William C Parks; Peter Chen
Journal:  Am J Respir Crit Care Med       Date:  2016-08-01       Impact factor: 21.405

8.  Molecular basis for the generation in pigs of influenza A viruses with pandemic potential.

Authors:  T Ito; J N Couceiro; S Kelm; L G Baum; S Krauss; M R Castrucci; I Donatelli; H Kida; J C Paulson; R G Webster; Y Kawaoka
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Verapamil inhibits influenza A virus replication.

Authors:  K M Nugent; J D Shanley
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

Review 10.  Interferon-stimulated genes and their antiviral effector functions.

Authors:  John W Schoggins; Charles M Rice
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

View more
  3 in total

1.  Exploration of Prognostic Biomarkers for Lung Adenocarcinoma Through Bioinformatics Analysis.

Authors:  Zhengliang Tu; Xiangfeng He; Liping Zeng; Di Meng; Runzhou Zhuang; Jiangang Zhao; Wanrong Dai
Journal:  Front Genet       Date:  2021-04-22       Impact factor: 4.599

2.  Smoking induces sex-specific changes in the small airway proteome.

Authors:  Spela Kokelj; Jörgen Östling; Benjamin Georgi; Karin Fromell; Kristina Nilsson Ekdahl; Henric K Olsson; Anna-Carin Olin
Journal:  Respir Res       Date:  2021-08-24

3.  Whole-genome sequencing in diverse subjects identifies genetic correlates of leukocyte traits: The NHLBI TOPMed program.

Authors:  Anna V Mikhaylova; Caitlin P McHugh; Linda M Polfus; Laura M Raffield; Meher Preethi Boorgula; Thomas W Blackwell; Jennifer A Brody; Jai Broome; Nathalie Chami; Ming-Huei Chen; Matthew P Conomos; Corey Cox; Joanne E Curran; Michelle Daya; Lynette Ekunwe; David C Glahn; Nancy Heard-Costa; Heather M Highland; Brian D Hobbs; Yann Ilboudo; Deepti Jain; Leslie A Lange; Tyne W Miller-Fleming; Nancy Min; Jee-Young Moon; Michael H Preuss; Jonathon Rosen; Kathleen Ryan; Albert V Smith; Quan Sun; Praveen Surendran; Paul S de Vries; Klaudia Walter; Zhe Wang; Marsha Wheeler; Lisa R Yanek; Xue Zhong; Goncalo R Abecasis; Laura Almasy; Kathleen C Barnes; Terri H Beaty; Lewis C Becker; John Blangero; Eric Boerwinkle; Adam S Butterworth; Sameer Chavan; Michael H Cho; Hélène Choquet; Adolfo Correa; Nancy Cox; Dawn L DeMeo; Nauder Faraday; Myriam Fornage; Robert E Gerszten; Lifang Hou; Andrew D Johnson; Eric Jorgenson; Robert Kaplan; Charles Kooperberg; Kousik Kundu; Cecelia A Laurie; Guillaume Lettre; Joshua P Lewis; Bingshan Li; Yun Li; Donald M Lloyd-Jones; Ruth J F Loos; Ani Manichaikul; Deborah A Meyers; Braxton D Mitchell; Alanna C Morrison; Debby Ngo; Deborah A Nickerson; Suraj Nongmaithem; Kari E North; Jeffrey R O'Connell; Victor E Ortega; Nathan Pankratz; James A Perry; Bruce M Psaty; Stephen S Rich; Nicole Soranzo; Jerome I Rotter; Edwin K Silverman; Nicholas L Smith; Hua Tang; Russell P Tracy; Timothy A Thornton; Ramachandran S Vasan; Joe Zein; Rasika A Mathias; Alexander P Reiner; Paul L Auer
Journal:  Am J Hum Genet       Date:  2021-09-27       Impact factor: 11.043

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.